Nykode Therapeutics

Less than 1K followers

NYKD

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

Nykode Therapeutics is a biotechnology company. The company specializes in the research and development of immunological therapies and vaccines. The solutions are mainly used for the treatment of patients with cancer and other serious health conditions that require long-term treatment. The largest operations are in the European market.

Market cap

-

Turnover

-

Revenue

98.39M

EBIT %

-556.8 %

P/E

-

Dividend yield-%

-

Financial calendar

25/2

2026

Annual report '25

All

Press releases

ShowingAll content types

Regulatory press release10 hours ago

Nykode Therapeutics ASA - Notice of Extraordinary General Meeting

Nykode Therapeutics

Regulatory press release10 hours ago

NYKD: Nykode Therapeutics Strengthens Board with the Nomination of Dr. Barbara Krebs-Pohl as New Chair of the Board and Dr. John Beadle as Board Member

Nykode Therapeutics

Regulatory press release11/24/2025, 3:40 PM

Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider

Nykode Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/24/2025, 6:00 AM

Nykode Therapeutics - Quarterly Report Q3 2025

Nykode Therapeutics

Regulatory press release11/13/2025, 7:00 AM

Nykode Therapeutics - Invitation to Q3 2025 Financial Results Presentation

Nykode Therapeutics

Regulatory press release11/5/2025, 6:00 AM

NYKD: Nykode Therapeutics to Present Data on the Strength of the Neoantigen Selection Method from Two Clinical Trials at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting

Nykode Therapeutics

Regulatory press release11/4/2025, 6:00 AM

NYKD: Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. Patent for the Neoantigen Selection Method for VB10.NEO, Nykode's Individualized Neoantigen Therapy

Nykode Therapeutics

Regulatory press release10/14/2025, 6:17 AM

Disclosure of Large Shareholding - Nykode Therapeutics ASA

Nykode Therapeutics

Regulatory press release10/10/2025, 3:44 PM

Nykode Therapeutics - Grant of Share Options

Nykode Therapeutics

Regulatory press release10/10/2025, 12:00 PM

Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider

Nykode Therapeutics

Regulatory press release10/10/2025, 10:36 AM

Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider

Nykode Therapeutics

Regulatory press release10/9/2025, 6:27 PM

NYKD: Financial calendar

Nykode Therapeutics

Regulatory press release8/27/2025, 5:01 AM

NYKD: Nykode Announces Updated Strategy to Increase Value for Patients and Shareholders, Prioritizing VB10.16 as the Lead Value Driver

Nykode Therapeutics

Regulatory press release8/27/2025, 5:00 AM

Nykode Therapeutics - Quarterly report Q2 2025

Nykode Therapeutics

Regulatory press release8/20/2025, 6:00 AM

Nykode Therapeutics - Invitation to Q2 2025 Financial Results Presentation and Strategy Update

Nykode Therapeutics

Regulatory press release7/9/2025, 4:15 PM

Nykode Therapeutics - Grant of Share Options

Nykode Therapeutics

Regulatory press release7/4/2025, 2:41 PM

NYKD: Financial calendar

Nykode Therapeutics

Regulatory press release5/28/2025, 5:00 AM

Nykode Therapeutics - Quarterly report Q1 2025

Nykode Therapeutics

Regulatory press release5/27/2025, 5:00 AM

Nykode Therapeutics ASA - Ex-dividend NOK 1.00 today

Nykode Therapeutics

Regulatory press release5/26/2025, 2:51 PM

Nykode Therapeutics - invitation to Q1 2025 financial results presentation

Nykode Therapeutics

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.